Robert F. Weir – författare

Who decides, and on what basis, how to treat a child with severe birth defects? Any decisions made on such cases are painful and complex, and have far-reaching consequences for society at large. Addressing the medical, legal, and ethical aspects of the issue, Robert Weir presents the first serious survey of the major arguments regarding selective non-treatment, which have been advanced by physicians, attorneys, and the judicial system.

This book provides a thorough, well-balanced analysis of common research practices with banked tissues, DNA, and genetic data. Describing many examples of beneficial tissue research, the authors focus on problematic research practices, controversial cases, and federal and institutional policies that limit the informed choices of patients and research participants. They offer a series of recommendations to help overcome these problems.

Genetics research with stored human tissues provides many benefits and holds much promise. Yet how this critical research is conducted sometimes raises serious ethical, legal, and social concerns, and it is difficult to balance the promise of biomedical research with our time-honored commitments to individual choice in such fundamental matters as control over personal health information and the disposition of our bodily tissues. Weir and Olick provide a thorough analysis of this critical phase in the era of genomic medicine. While strongly supportive of the biomedical research enterprise, they develop a critique of many common research practices with banked tissues, DNA, and genetic data. Noting numerous examples of beneficial human tissue research, they focus on problematic research practices, controversial cases, and federal and institutional policies that limit the informed choices of patients and research participants. The authors offer a series of recommendations intended to limit the risks of inadequate informed consent to research for individuals, families, and groups, and to strengthen the bonds of trust between the research enterprise and the public upon which biomedical progress depends. This book offers a wealth of information plus well-reasoned recommendations that will be of keen interest to geneticists, other biomedical scientists, research institutions, policymakers, students and others. It will serve as a clarion call to move beyond traditional policies and practices toward a richer understanding of partnership between patients and research participants and the biomedical research enterprise - a partnership for the benefit of all.